TY - JOUR
T1 - Molecular pathways
T2 - Targeting the kinase effectors of RHO-family GTPases
AU - Prudnikova, Tatiana Y.
AU - Rawat, Sonali J.
AU - Chernoff, Jonathan
N1 - Publisher Copyright:
©2014 AACR.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - RHO GTPases, members of the RAS superfamily of small GTPases, are adhesion and growth factor-activated molecular switches that play important roles in tumor development and progression. When activated, RHO-family GTPases such as RAC1, CDC42, and RHOA, transmit signals by recruiting a variety of effector proteins, including the protein kinases PAK, ACK, MLK, MRCK, and ROCK. Genetically induced loss of RHO function impedes transformation by a number of oncogenic stimuli, leading to an interest in developing small-molecule inhibitors that either target RHO GTPases directly, or that target their downstream protein kinase effectors. Although inhibitors of RHO GTPases and their downstream signaling kinases have not yet been widely adopted for clinical use, their potential value as cancer therapeutics continues to facilitate pharmaceutical research and development and is a promising therapeutic strategy.
AB - RHO GTPases, members of the RAS superfamily of small GTPases, are adhesion and growth factor-activated molecular switches that play important roles in tumor development and progression. When activated, RHO-family GTPases such as RAC1, CDC42, and RHOA, transmit signals by recruiting a variety of effector proteins, including the protein kinases PAK, ACK, MLK, MRCK, and ROCK. Genetically induced loss of RHO function impedes transformation by a number of oncogenic stimuli, leading to an interest in developing small-molecule inhibitors that either target RHO GTPases directly, or that target their downstream protein kinase effectors. Although inhibitors of RHO GTPases and their downstream signaling kinases have not yet been widely adopted for clinical use, their potential value as cancer therapeutics continues to facilitate pharmaceutical research and development and is a promising therapeutic strategy.
UR - http://www.scopus.com/inward/record.url?scp=84920517234&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-0827
DO - 10.1158/1078-0432.CCR-14-0827
M3 - Article
C2 - 25336694
SN - 1078-0432
VL - 21
SP - 24
EP - 29
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -